ACE-031, at a dosage of 1mg, is now generating substantial interest across the continent . Clinical trials in several countries have demonstrated a potential profile for addressing specific disorders. Regulatory pathways are under review in multiple major EU member regions, with anticipation for eventual distribution following completion of plan… Read More